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Abstract 
Excess reactive oxygen species (ROS) generation and inflammation may contribute to obesity-
associated skeletal muscle insulin resistance. Ghrelin is a gastric hormone whose unacylated 
(UnAG) form is associated with whole-body insulin sensitivity in humans and may reduce 
oxidative stress in non-muscle cells in-vitro. We hypothesized that UnAG 1) lowers muscle ROS 
production and inflammation and enhances tissue insulin action in lean rats; 2) prevents muscle 
metabolic alterations and normalizes insulin resistance and hyperglycemia in high-fat diet 
(HFD)-induced obesity. In 12-week-old lean rats, UnAG (4-day, twice-daily subcutaneous 
200µg-injections) reduced gastrocnemius mitochondrial ROS generation and inflammatory 
cytokines while enhancing AKT-dependent signaling and insulin-stimulated glucose uptake. In 
HFD-treated mice, chronic UnAG overexpression prevented obesity-associated hyperglycemia 
and whole-body insulin resistance (insulin-tolerance test), as well as muscle oxidative stress, 
inflammation and altered insulin signalling. In myotubes, UnAG consistently lowered 
mitochondrial ROS production and enhanced insulin signalling, while UnAG effects were 
prevented by siRNA-mediated silencing of the autophagy mediator ATG5. Thus, UnAG lowers 
mitochondrial ROS production and inflammation while enhancing insulin action in rodent 
skeletal muscle. In HFD-induced obesity, these effects prevent hyperglycemia and insulin 
resistance. Stimulated muscle autophagy could contribute to UnAG activities. These findings 
support UnAG as a therapeutic strategy for obesity-associated metabolic alterations. 
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Introduction 
Clustered metabolic abnormalities including excess reactive oxygen species (ROS) generation 
and inflammation activation are proposed contributors to the onset of skeletal muscle insulin 
resistance (1-5). Excess muscle ROS production and inflammation are indeed linked at the level 
of IκB/NF-κB activation and may cause insulin resistance by inhibiting insulin signalling 
downstream of insulin receptor (2,3,5). Ghrelin is a peptide hormone predominantly secreted by 
the stomach whose acylated form (AG) is a major hypothalamic orexigenic signal (6,7). 
Sustained AG administration causes weight gain and hyperglycemia despite enhanced muscle 
mitochondrial oxidative capacity (8,9) by increasing food intake, hepatic gluconeogenesis and fat 
deposition in rodents (10,11). A comprehensive understanding of the metabolic impact of ghrelin 
has been however recently allowed by reports of independent more favourable effects of its 
unacylated form (UnAG). Although no specific UnAG receptor has been yet identified, UnAG 
counteracts glucogenic effects of AG as well as AG-induced hyperglycemia (10), and negative 
associations have been reported between circulating UnAG and markers of whole-body insulin 
resistance in humans (12,13). Emerging antioxidant effects have been interestingly reported for 
UnAG in different cell types (14-17) and we recently demonstrated that UnAG stimulates 
autophagy in rodent muscle, thereby also potentially lowering muscle oxidative stress through 
disposal of damaged mitochondria (18). No information is however available 1) on the impact of 
UnAG on skeletal muscle ROS generation, inflammation and insulin action; 2) on whether 
UnAG prevents altered oxidative stress, inflammation and insulin action in obesity and diabetes. 
We therefore studied lean rats and a transgenic mouse model of systemic UnAG overproduction 
(19) to test the hypothesis that UnAG 1) lowers mitochondrial ROS production and inflammation 
and enhances insulin action in lean rodent muscle; 2) normalizes high-fat diet (HFD)-induced 
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muscle metabolic alterations, whole-body insulin resistance and hyperglycemia. In addition, 
effects of UnAG were verified in vitro in myotubes, where we also mechanistically tested the 
hypothesis that UnAG activites are at least partly mediated by positive modulation of autophagy. 
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Research Design and Methods 
Experimental design 
Exogenous UnAG administration Experiments were approved by the Animal Studies Committee 
at Trieste University. Twenty 12-week-old male Wistar rats (Harlan-Italy, San Pietro-al-
Natisone, Udine, Italy) were housed for two weeks in individual cages with a 12-h light–dark 
cycle at the University Animal Facility, with ad-libitum water and standard chow (Harlan 2018, 
14.2 kJ/g). Animals were then randomly assigned to 4-day, twice-daily 200µg-subcutaneous 
injections of UnAG (n=10, Bachem, Bubendorf, CH) or vehicle (Ct, n=10, NaCl 0,9% w/v). 
UnAG dose was based on previous studies in which equimolar AG modulated the same 
parameters (8). Body weight and food intake were monitored daily; after the last injection, food 
was removed for three hours followed by anaesthesia (Tiobutabarbital 100 mg/kg, 
Tiletamine/Zolazepam (1:1) 40 mg/kg IP). Gastrocnemius and extensor digitorum longus (EDL) 
muscles were then surgically isolated and blood collected by heart puncture. 
Transgenic UnAG overexpression Generation and characteristics of transgenic mice 
overexpressing UnAG (Tg Myh6/Ghrl) were previously described (19). Selective ghrelin 
overproduction in the heart, characterized by negligible acylating activity, results in 40-fold 
increment in circulating UnAG without AG modification. 14 Tg Myh6/Ghrl and 14 matched 
wild-type male mice underwent 16-week standard or HFD feeding (10% or 60% calories from 
fat; Research Diets, New Brunswick, NJ), and were sacrificed as described above. Insulin 
tolerance tests (ITT) were performed at 15 weeks of treatment by intraperitoneal insulin injection 
(Humulin-R, Lilly, Indianapolis, IN; 3 nmol/kg) after 4-h fasting. Blood glucose was measured 
from tail blood (AccuCheck Active, Roche, Basel, CH) immediately prior to injection and at 20, 
40, 60, 80 min. 
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Myotube experiments C2C12 myoblasts were differentiated in myotubes (20). After 4-day 
incubation with differentiation medium and 18h-starvation, cells were treated with AG or UnAG 
(0.1, 0.5, 1µmol/l) for 48 h, collected and processed. In additional experiments, the potential role 
of autophagy in effects of UnAG was investigated by genomic silencing of the autophagy 
mediator ATG5 (18). SiRNA knockdown of ATG5 was performed by reverse transfection at 
final 25nM concentration with mouse ATG5 siRNA (M-064838-02-0005; Dharmacon) or with a 
non-targeting control siRNA #4 (D-001210-04-20; Dharmacon) using Lipofectamine 
RNAiMAX (Life Technologies). Twenty-four hours after transfection, culture medium was 
replaced and after thirty-six hours differentiated, treated and processed as above. ATG5 protein 
levels were quantified by western blot. 
Analytical methods 
Plasma insulin and non-esterified fatty acids (NEFA) Plasma insulin concentration was measured 
by ELISA (Ultrasensitive ELISA, DRG, Springfield, NJ). Plasma glucose and NEFA were 
determined by standard enzymatic-colorimetric assays (21,22).  
Ex vivo redox state Mitochondrial H2O2 production was assessed in isolated intact mitochondria 
from tissues and cells using the Amplex Red (10µmol/l, Invitrogen, Carlsbad, CA)-HRP method, 
modified as previously reported and normalised by citrate synthase (CS) activity in the same 
mitochondrial preparation (22,23). Assay substrate concentrations (mmol/l) were: 8 glutamate, 4 
malate (GM); 10 succinate (S); 4 glutamate, 2 malate, 10 succinate (GMS); 0.05 palmitoyl-L-
carnitine, 2 malate (PCM). Superoxide anion production sources in gastrocnemius muscle whole-
tissue homogenate were assessed using the lucigenin chemiluminescent method as described (22) 
and normalised by protein concentration (BCA assay, Pierce, Rockford IL, USA). The impact of 
subsequent addition of specific inhibitors on specific substrate-stimulated production rates was 
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used to evaluate relative superoxide production from each source (Mitochondria: 5µmol/l CCCP 
on Succinate; NOS: 10mmol/l L-NAME on 10mmol/l L-Arginine; NADPH Oxidase: 200µmol/l 
DPI on 1mmol/l NADPH; Xanthine oxidase: 200µmol/l Oxypurinol on 500µmol/l Xanthine) as 
referenced. 
Glutathione and antioxidant enzyme activities Total and oxidised glutathione were determined as 
referenced (24) on ~50mg of gastrocnemius cleaned and homogenised in ice-cold 5% (wt/vol.) 
metaphosphoric acid (20ml/g tissue). Reduced glutathione (GSH) was calculated as total minus 
oxidised fraction (GSSG). Commercial kits were used to measure catalase (Amplex Red Catalase 
Assay, Invitrogen, Carlsbad, CA) and glutathione peroxidase activities (Abcam, Cambridge, 
UK). 
Protein analyses 
-xMAP Cytokine profile and insulin signalling protein phosphorylation at IRY1162/Y1163, IRS-
1S312,  AKTS473, GSK-3βS9, PRAS40T246 and P70S6KT421/S424 levels were measured by xMAP 
technology (Magpix, Luminex Corporation, Austin, TX) using commercial kits, validated by 
manufacturer for multiplexing profiling (LRC0002M; LHO0001M; LHO0002, Life 
Technologies, Carlsbad, CA). Milliplex Analyst software (Millipore, Billerica, MA) was used for 
interpolating data to standard curve. Phosphorylation of each protein is expressed as phospho-
protein units/total pg. 
-Western Blot Western Blots were performed as described (21,22,25). Equal loading was 
checked by Ponceau-S staining and GAPDH reprobing. Primary antibodies dilutions were: anti-
MnSuperoxide Dismutase (SOD) and anti-CuZnSOD (Stressgen, Ann Arbor, MI) 1:5000 and 
1:1000 respectively; anti-IκB (Cell Signaling, Beverly, MA) 1:500; anti-pIRS-1Y612 (Abcam, 
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Cambridge, UK) 1:500; anti-ATG5 (Cell Signaling) 1:2000; anti LC3B (Sigma) 1:1500; anti-b-
Actin (Sigma) 1:25000 and anti-GAPDH (Santa Cruz, Dallas, TX) 1:1000.  
Electrophoretic mobility shift assay (EMSA) NF-κB binding activity was assessed by non-
radioactive EMSA (22) with modifications. Equal amounts of nuclear protein were loaded for 
each sample. After incubation with polydeoxyinosinic-deoxycytidylic acid (0.05µg/µl) and 
double-stranded 3′-biotinylated DNA probe, electrophoretic separation of nuclear extracts was 
performed in 0.8% agarose gel. Band specificity evaluation and identification was performed by 
running a pooled sample pre-incubated for 20 min with excess unlabelled probe (1000x), anti-
p65 (Millipore; 2µg) or anti-p105/p50 (Abcam; 2µg) antibody. Results were calculated from 
optical density of NF-κB specific bands. 
Tissue Glucose uptake Tissue glucose uptake was measured ex-vivo with non-radioactive 2-
deoxyglucose (2-DG) (26). EDL muscle is metabolically largely similar to gastrocnemius (27) 
and was used because of smaller diameter and better exchange with incubation buffer (28). Two 
muscle sections were incubated for 30’ at 37°C under constant oxygenation with or without 
insulin (Humulin-R 600pmol/l) in isotonic buffer, pH=7.4, added with BSA (1mg/ml) and 
pyruvate (2mM). After 20-min incubation with pyruvate substituted with 2-DG (1mM), samples 
were snap frozen and kept at -80°C. After homogenization in ultrapure water followed by NaOH 
addition (0.07N), enzymes and endogenous NAD(P)H and NAD(P) were inactivated by 45-min 
incubation at 85°C. Equinormal quantities of HCl were then added, samples were cleared from 
debris by centrifugation (10000xg, 5min) and transferred to 96-well microplates for incubation 
(37°C, 60min) in assay buffer, added with (Buffer C) β-NADP (0.1mM) and Glucose-6-
phosphate dehydrogenase from L. Mesenteroides (G6PDH, 20U/ml) or (Buffer D) with β-NAD 
0.1mM and G6PDH (0.3U/ml). Concentrations of G6P and G6P+2-DG6P were quantified by 
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fluorimetrically measuring (Infinite F200, Tecan, Männedorf, CH) conversion of Resazurin in 
Resorufin in Buffers C and D, respectively. Values related to 2-DG6P were calculated by 
subtraction, interpolated on a standard curve of 2-DG6P, and normalized by protein 
concentration in sample homogenate. Tissue 2-DG6P uptake was expressed in µmol of 2-DG/mg 
protein/30min. 
ATP synthesis and complex-related ATP production  ATP synthesis rate was measured in tissues 
and cells ex-vivo in freshly isolated mitochondria using a luciferin-luciferase luminometric assay 
(22). Integrity of mitochondria isolated by gentle homogenization was tested by comparison of 
citrate synthase measurements in samples before and after membrane disruption (29). After 
signal stabilization and excess substrates addition a first 10-min kinetic read was performed, 
followed by 100µmol/l ADP addition and 20-min read. Final respiration substrates composition 
and reaction concentrations (mmol/l) were: 0.25 pyruvate, 0.0125 palmitoyl-L-carnitine, 2.5 α-
ketoglutarate, 0.25 malate (PPKM); 0.025 palmitoyl-L-carnitine, 0.5 malate (PCM); 20 succinate, 
0.1 rotenone (SR); 10 glutamate, 5 malate (GM). The impact of complex-related energy flux on 
ATP synthesis was calculated as the difference in production rate induced by the addition, in a 
subsequent 20-min read, of a complex-specific inhibitor during state-3 respiration on excess 
complex-specific substrate. For complex I-related ATP synthesis, substrate and inhibitor were 
GM and rotenone (2µmol/l), while for complex II SR and malonate (1mmol/l). Mitochondrial 
functional integrity in each preparation was confirmed by a >80% and >95% decrease in state 3 
ATP synthesis after addition of CCCP 30µM and oligomycin 2µg/µl respectively. Values were 
then normalized by ATP synthesis rate with the non-specific substrate PPKM, and data presented 
as the ratio between values obtained for complex I-related over complex II-related results. 
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Statistical analysis Groups were compared using Student t-test or one-way ANOVA followed by 
appropriate post-hoc tests. Bonferroni correction for multiple comparisons was applied. p<0.05 
was considered statistically significant. 
Results 
EXOGENOUS UnAG ADMINISTRATION 
Animal characteristics In lean adult rats, exogenous 4-day UnAG did not modify body weight 
(Ct:319.6±3.6g; UnAG:324.1±6.1g), weight gain during treatment (Ct:13.0±1.4g; 
UnAG:11.6±1.1g) or caloric intake (Ct: 76.9±2.3kcal/d; UnAG: 73.5±1.8kcal/d). Plasma glucose 
(Ct: 118.6±6.0mg/dL; UnAG: 120.5±7.5mg/dL), insulin (Ct: 12.8±2.1µU/ml; UnAG: 
14.3±2.9µU/ml) and NEFA (Ct: 0.27±0.06mmol/L; UnAG: 0.21±0.03mmol/L) concentrations 
were comparable among groups. 
UnAG lowers skeletal muscle ROS production UnAG lowered gastrocnemius H2O2 and 
superoxide anion production rate, and this effect involved mitochondrial respiration-dependent 
ROS generation (Figure1A-C). NOS-dependent but not xanthine- or NADPH oxidase-dependent 
superoxide production was also reduced by UnAG (Figure 1D-F). UnAG-treated rats also had 
lower muscle oxidized-over-total glutathione, a marker of tissue redox state (Figure 1G-H). 
Tissue protein levels of SOD isoforms and activities of antioxidant catalase and glutathione 
peroxidase were conversely not modified by UnAG (Figure 1I-L).  
UnAG lowers tissue inflammation Protein expression of the NF-κB inhibitor IκB was higher in 
UnAG- compared to saline-treated rats, with parallel reduction of pro-inflammatory NF-κB 
p65/p50 nuclear binding activity (Figure 2A-B). UnAG also increased p50/p50 homodimer 
binding activity (Figure 2B), a transcription activator for anti-inflammatory IL-10 (30). UnAG 
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treatment consistently resulted in anti-inflammatory changes in muscle cytokine patterns, with 
higher IL-10 expression and lower pro-inflammatory IL-1a and TNFα (Figure 2C-G). 
UnAG enhances insulin signalling and glucose uptake UnAG also led to insulin signaling 
activation with increased phosphorylation of AKTS473, GSK-3βS9, PRAS40T246 and 
P70S6KT421/S424 (Figure 3A-F), consistent with activation of both mTORC complexes kinase 
activity. Changes in insulin signalling were paralleled by higher insulin-stimulated muscle 
glucose uptake (Figure 3G). These effects were further associated with enhanced IRS-1S312 
phosphorylation (Figure 3B), an mTORC-dependent negative feedback mechanism and marker 
for enhanced insulin signaling (31). To determine whether activating IRS-1 phosphorylations 
were also enhanced, we measured pIRS-1Y612 and found no stimulation in UnAG-treated animals 
(Supplementary Figure 1A), further indicating that UnAG-associated activation of insulin 
signalling occurs downstream of mTORC complexes but not at IR-IRS1 level.  
In vivo effects of UnAG are tissue-specific In liver tissue, a non-statistically significant reduction 
in mitochondrial superoxide production was observed. This relatively minor change was not 
associated with altered redox state, inflammation markers or insulin signalling (Supplementary 
Figures 2A-I, 3A-F), as previously shown (32,33).  
TRANSGENIC UnAG OVEREXPRESSION AND HFD-INDUCED OBESITY  
Animal characteristics Up-regulation of circulating UnAG by myocardial overexpression of the 
ghrelin gene (Tg Myh6/Ghrl) (19) did not modify body weight (Control-Diet: Ct: 31.0±2.1g; Tg 
Myh6/Ghrl: 28.7±2.1g; HFD: Ct: 37.9±3.0g; Tg Myh6/Ghrl: 36.6±1.1g) or caloric intake 
(Control-Diet: Ct: 13.5±0.1kcal/d; Tg Myh6/Ghrl: 14.6±0.6kcal/d; HFD: Ct: 17.6±0.1kcal/d; Tg 
Myh6/Ghrl: 17.9±0.5kcal/d) under any dietary regimen (19). Blood glucose (Control Diet: Ct: 
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106.0±7.3mg/dL; Tg Myh6/Ghrl: 98.2±8.0mg/dL), plasma insulin (Control Diet: Ct: 
13.3±1.8µU/ml; Tg Myh6/Ghrl: 14.5±3.1µU/ml;) and NEFA (Control Diet: Ct: 
0.32±0.06mmol/L; Tg Myh6/Ghrl: 0.38±0.08mmol/L) were also comparable among lean groups. 
In contrast, blood glucose (HFD Ct: 161.9±30.7mg/dL; Tg Myh6/Ghrl: 102.7±11.6mg/dL; 
P<0.05 Ct vs Tg Myh6/Ghrl) and plasma insulin (HFD: Ct: 25.1±2.2µU/ml; Tg Myh6/Ghrl: 
16.5±1.6µU/ml; P<0.05 Ct vs Tg Myh6/Ghrl) while not NEFA (HFD: Ct: 0.27±0.05mmol/L; Tg 
Myh6/Ghrl: 0.32±0.10mmol/L; P=NS) were lower in HFD-obese Tg Myh6/Ghrl compared to 
both wild-type HFD animals and lean groups (P=NS HFD Tg Myh6/Ghrl vs lean groups). 
Systemic circulating UnAG up-regulation prevents obesity-associated hyperglycemia, whole-
body insulin resistance and skeletal muscle oxidative stress, inflammation and impaired AKT 
phosphorylation Consistent with exogenous UnAG administration, circulating UnAG up-
regulation in Tg Myh6/Ghrl was characterized by lower muscle oxidized-to-total glutathione, 
less pro-inflammatory tissue cytokine profile and more pronounced phosphorylation of AKTS473, 
GSK-3βS9, PRAS40T246 and P70S6KT421/S424 (Figure 4A-M). These effects were associated with 
higher insulin sensitivity by area-under-the-curve (AUC) for ITT-induced blood glucose changes 
(Figure 4N-P). Obese wild-type animals were expectedly hyperglycemic and insulin resistant 
(Figure 4N-P). The obese wild-type group also had higher oxidized-to-total glutathione, pro-
inflammatory cytokine profile and reduced phosphorylation of AKTS473 and GSK-3βS9 in 
gastrocnemius (Figure 4A-M). Compared to lean Tg Myh6/Ghrl, obese Tg Myh6/Ghrl had 
moderately higher muscle oxidized-to-total glutathione and TNFα, that however remained lower 
(P<0.05) than obese and comparable (P=NS) to lean wild-type animals (Figure 4B,4E). In 
addition, UnAG upregulation prevented obesity-associated increments (P<0.05 vs obese wild-
type) in muscle pro-inflammatory cytokines IL-1α and IL-1β with lower IL-6, and resulted in 
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normalized activating phosphorylation at AKTS473 and GSK-3βS9 levels (P=NS vs lean Tg 
Myh6/Ghrl). Importantly, obese Tg Myh6/Ghrl were protected from obesity-induced 
hyperglycemia and whole-body insulin resistance (Figure 4N-P), with both parameters 
superimposable to lean wild-type animals. Insulin signalling proteins upstream of AKT were not 
activated in Tg Myh6/Ghrl, with patterns of pIRS-1S312 and pIRS-1Y612 comparable to those 
observed in exogenously-treated animals (Figure 4H-I, Supplementary Figure 1B). 
 
IN VITRO MYOTUBE EXPERIMENTS 
UnAG effects on ROS production and insulin signalling are confirmed in C2C12 myotubes 48-
hour UnAG treatment of C2C12 myotubes lowered mitochondrial ROS generation with largely 
dose-dependent effects (Figure 5A). Also consistently with in vivo data, UnAG resulted in 
increased activating phosphorylation of mTORC complexes-dependent insulin signaling proteins 
AKTS473, GSK-3βS9, PRAS40T246 and P70S6KT421/S424. Patterns of pIRY1162/Y1163 and pIRS-1S312 
were also comparable in C2C12 and in-vivo experiments, supporting lack of activation of IR-
IRS1 (Figure 5B-G).  
UnAG effects in vitro are not shared by AG C2C12 myotubes do not appear to express the AG 
receptor GHSR1 (34). To further exclude the possibility that UnAG-induced changes result from 
non-specific activation of additional AG-regulated pathways, C2C12 experiments were 
performed with equimolar AG concentrations. 48-hour AG incubation failed to inhibit ROS 
production and to activate insulin signalling except for less pronounced enhancement of pGSK-
3βS9 (Figure 5A-G).  
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UnAG effects in vitro are abolished by silencing the autophagy mediator ATG5 In additional 
experiments, C2C12 myotubes were incubated with UnAG after genomic silencing of the 
autophagy mediator ATG5. ATG5 silencing abolished UnAG activities on both mitochondrial 
ROS production and insulin signalling (Figure 6A-H). Levels of the autophagy activation marker 
LC3II/LC3I were also higher in HFD-obese Tg Myh6/Ghrl than wild-type mice (Figure 6I). 
 
MITOCHONDRIAL ATP PRODUCTION 
Effects of UnAG are not associated with enhanced skeletal muscle mitochondrial function 
Consistent with previous results (22,35), UnAG-induced changes in redox state, inflammation 
and insulin signalling were not associated with enhanced, but rather with lower or unchanged 
ATP production rate in vivo and in vitro respectively (Figure 7A-C). Higher skeletal muscle 
ATP production was observed in obese mice compared to lean counterparts, but UnAG up-
regulation was associated with lower ATP production rates also in obese animals (Figure 7B). 
UnAG modified muscle respiratory chain complex-related ATP production by shifting ATP 
synthesis towards complex I over complex II both in vivo and in vitro (Figure 7D-E). Differently 
from UnAG, AG enhanced ATP production in C2C12 myotubes (Figure 7C). Liver ATP 
production was not modified by UnAG (Supplementary Figure 3G). 
Discussion 
 
These studies demonstrated that 1) sustained UnAG administration in vivo leads to a) lower 
muscle ROS production and less oxidized tissue redox state; b) anti-inflammatory changes in 
tissue NF-κB activation and cytokine patterns; c) enhanced mTORC-dependent insulin signalling 
with higher insulin-stimulated muscle glucose uptake. 2) Muscle effects of UnAG are 
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reproduced in a model of systemic circulating UnAG up-regulation with HFD-induced obesity, 
resulting in prevention of obesity-associated hyperglycemia and whole-body insulin resistance. 
3) UnAG effects are dose-dependently confirmed in myotubes; differential effects of AG and 
UnAG are observed in vitro, thereby indicating that UnAG acts at least partly directly and 
independently of AG-regulated pathways. Finally, UnAG effects in vitro are abolished by 
autophagy inhibition, thereby indicating mechanistic involvement of autophagy in UnAG 
activities. 
 
The current results show that UnAG negatively regulates skeletal muscle ROS production and 
inflammation, and these effects are indirectly supported by previous in vitro observations in non-
muscle cells (14,16,19). In a recent study, UnAG reduced endothelial oxidative stress in models 
of peripheral artery disease by restoring SOD expression (15,16). Skeletal muscle SOD 
expression and antioxidant enzyme activities were however unchanged by UnAG in the current 
model, indicating lower mitochondrial ROS generation rather than enhanced antioxidant 
defenses as a key mediator of UnAG-induced muscle antioxidant activity. Since we recently 
identified UnAG as a potent inducer of autophagy in cardiomyocytes and myotubes (35), 
enhanced removal of dysfunctional mitochondria could have contributed to lower tissue 
oxidative load in the current experimental setting. This hypothesis was notably confirmed in 
myotubes experiments using siRNA-mediated autophagy inhibition. Among less quantitatively 
relevant ROS sources (36), UnAG selectively inhibited NOS-dependent superoxide production. 
This finding is intriguingly consistent with emerging co-localization and functional interactions 
between NOS, nitric oxide (NO) and muscle mitochondria (37,38). In particular, NO production 
has been reported to enhance mitochondrial ROS generation (37) while UnAG was reported to 
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reduce NO production induced by pro-inflammatory cytokines in various settings (39). Potential 
interactions between UnAG, NO and mitochondrial ROS generation should be directly 
investigated in future studies. 
Sustained UnAG administration enhanced skeletal muscle insulin signalling downstream of 
mTORC complexes while not at IR-IRS-1 level, and these effects were paralleled by increased 
insulin-stimulated muscle glucose uptake. These changes are importantly in excellent agreement 
with, and provide a molecular basis for, clinical observations linking UnAG with preserved 
whole-body insulin sensitivity in humans (12,13). Interestingly, autophagy inhibition in vitro 
abolished UnAG activities on both mitochondrial ROS production and insulin signalling. These 
observations provide further strong support for a causal negative impact of mitochondrial ROS 
production on AKT-dependent insulin signalling, in agreement with previous observations (1-5). 
Intriguingly, UnAG effects were associated with enhanced inhibitory IRS-1S312 phosphorylation. 
This seemingly paradoxical observation is however consistent with recent reports of IRS-1S312 
phosphorylation as a physiological negative feedback modulation following downstream 
signalling activation (31).  
Results in Tg Myh6/Ghrl mice with chronic systemic UnAG over-exposure (19) confirmed 
effects of exogenous UnAG administration, and these results are supported by higher insulin 
sensitivity in a lean UnAG adipose transgenic model (17). Since plasma AG and IGF-1 are 
unchanged in Tg Myh6/Ghrl (19), our findings further confirm that UnAG effects are 
independent of changes in AG and its potential impact on GH-IGF1 through GHSR1 (7,19). 
Most importantly, circulating UnAG upregulation prevented HFD-induced hyperglycemia and 
systemic insulin resistance, while muscle oxidative stress markers, inflammation and impaired 
insulin signalling were overall preserved at levels comparable with lean Tg Myh6/Ghrl or wild-
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type animals. UnAG-dependent stimulation of muscle autophagy was also confirmed in vivo in 
HFD-obese Tg Myh6/Ghrl by higher LC3II/LC3I ratio, and could therefore have potentially 
directly contributed to beneficial effects of UnAG overexpression (40). Interestingly, obese Tg 
Myh6/Ghrl animals showed no increments in pIRS-1S312 compared to wild-type counterparts, 
and lack of effect was associated with lack of stimulation of insulin signalling activation at 
P70S6K levels. These combined observations are consistent with the hypothesis that IRS-1S312 
phosphorylation is at least partly mediated by this feedback loop (31). Potential mechanisms 
underlying differential regulation of PRAS40T246 and P70S6KT421/S424 phosphorylation in obese 
vs lean models of UnAG exposure should be investigated in future studies. Overall, results in the 
HFD-obesity model importantly demonstrate that effects of UnAG translate into beneficial 
metabolic changes in a clinically relevant model of dietary-induced insulin resistance and 
hyperglycemia, thereby providing a strong rationale for therapeutic strategies to increase UnAG 
availability in obese, insulin resistant and type 2 diabetic conditions.  
Myotubes experiments were in excellent agreement with in vivo studies in showing 
superimposable effects of UnAG on ROS production and insulin signalling, that were not 
induced by equimolar AG concentrations. These observations strongly indicate that UnAG 
directly stimulates skeletal muscle insulin signaling and they are consistent with previously-
reported UnAG signaling and anti-atrophic activities in skeletal muscle of both wt and GHSR1 
knockout mice (19). These findings overall provide strong support to the hypothesis that UnAG 
effects in skeletal muscle are independent of GHSR1 and are mediated by alternative, yet-
unidentified UnAG receptor(s). It should also be pointed out that both AG and UnAG stimulate 
differentiation of C2C12 myoblasts (34), and that both ghrelin forms enhance mTORC2-
mediated anti-atrophic signalling under acute experimental conditions in C2C12 myotubes as 
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well as in vivo in skeletal muscle of GHSR KO mice (19, 32). In the current studies with 
prolonged hormone incubation, highest AG doses selectively induced a moderate increase of 
GSK-3βS9 phosphorylation but they failed to reduce ROS generation and to enhance downstream 
insulin signaling. Also consistent with these findings, AG is a weaker autophagy inducer than 
UnAG and it fails to stimulate both mitophagy (35) and ischemia-induced skeletal muscle 
regeneration (15). Based on available knowledge, differential muscle effects of ghrelin forms 
may depend on still uninvestigated acylation-selective and time-dependent AG activities. 
Overall, differential effects of ghrelin forms on muscle insulin signalling are fully consistent with 
clinical observations linking UnAG, but not AG to whole-body insulin sensitivity in humans 
(12,13).  
It should be finally pointed out that UnAG-induced lower ROS production, lower inflammation 
and enhanced insulin signalling were associated with reduced or unchanged ATP production. In 
agreement with previous studies, high-fat fed animals conversely showed higher mitochondrial 
ATP production despite higher oxidative stress markers and insulin resistance (32), and this 
alteration could involve enhanced substrate availability through feed-forward mechanisms (32). 
Our results therefore provide further evidence against a role for low mitochondrial function to 
primarily cause insulin resistance (41-45), conversely indicating UnAG as a novel modulator of 
muscle mitochondrial activity with negative impact on both ATP and ROS production in vivo. 
Unchanged mitochondrial ATP production in vitro however does not support a direct role of 
UnAG to inhibit mitochondrial function, while it further indicates that reduced mitochondrial 
function is not a prerequisite for reduced ROS generation. Interestingly, UnAG modified 
complex-related ATP production by favoring complex I over complex II-related synthesis in 
vitro and in vivo, potentially reflecting preferential glucose over fat-derived substrate oxidation 
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(46). Since glucose-related substrate oxidation may lower mitochondrial ROS generation 
(47,48), this mechanism could also contribute to inhibit ROS production. Further studies on 
interactions between UnAG and muscle mitochondrial function are warranted by the current 
results. 
In conclusion, these studies demonstrated a novel role of UnAG to modulate skeletal muscle 
redox state, inflammation and insulin signalling. UnAG-treated rat muscle is characterized by 
lower mitochondrial ROS production, lower inflammation and enhanced insulin signalling and 
action. These effects are tissue-specific, they appear to be direct and independent of acylated 
hormone, and they could be at least partly mediated by UnAG-dependent stimulation of 
autophagy (Figure 8). UnAG overexpression also prevents obesity-associated hyperglycemia and 
systemic insulin resistance as well as muscle oxidative stress, inflammation activation and 
impaired insulin signalling. The current findings collectively indicate UnAG as a potential novel 
treatment for obesity-associated metabolic alterations. 
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Figure Legends 
Figure 1. UnAG and skeletal muscle redox state. Effects of unacylated ghrelin (UnAG, 200µg 
subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day treatment on overall (A) and 
specific superoxide production from mitochondrial sources in whole tissue homogenate (B), on 
intact isolated mitochondrial H2O2 synthesis rate with different respiratory substrates (C, GMS: 
Glutamate+Succinate+Malate; S: Succinate; GM: Glutamate+Malate; PCM: Palmitoyl-L-
Carnintine+Malate) and on superoxide generation from nitric oxide synthase (D), NADPH oxidase 
(E) and xanthine oxidase (F) in skeletal muscle. Effects of UnAG treatment on total (G) and 
oxidized (GSSG) over total (H, GSH: reduced) tissue glutathione, effects of UnAG on protein 
expression of Cu/ZnSOD (I) and MnSOD (J) with representative blots, and on enzyme activities of 
catalase (K) and glutathione peroxidase (GPx; L). U CS: units of citrate synthase; a.u.: arbitrary 
units. *p<0.05 vs. Ct; mean±SEM, n=8-10/group.  
Figure 2. UnAG and skeletal muscle inflammation. Effects of unacylated ghrelin (UnAG, 200µg 
subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day treatment on the expression of 
IκB (A), on NF-κB binding activity (B) with representative blots, and on tissue expression of IL-1α 
(C), IL-1β (D), TNFα (E), IL-6 (F) and IL-10 (G) measured by xMAP technology in 
gastrocnemious muscle. a.u.: arbitrary units, Ab: antibody. *p<0.05 vs. Ct; mean±SEM; n=8-
10/group. 
Figure 3. UnAG and skeletal muscle insulin action. Effects of unacylated ghrelin (UnAG, 200µg 
subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day treatment on the 
phosphorylation measured by xMAP technology of insulin receptor (IRY1162/Y1163, A), IRS-1S312 (B), 
AKTS473 (C), GSK-3βS9 (D), PRAS40T246 (E), P70S6KT421/S424 (F) and on tissue glucose uptake (G) 
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in gastrocnemious muscle. *p<0.05 vs. Ct; †p<0.05 vs. same treatment Insulin-; ‡p<0.05 vs. other 
treatment Insulin-; mean±SEM, n=8-10/group. 
Figure 4. Impact of systemic overexpression of UnAG on skeletal muscle redox state, 
inflammation, insulin signaling and action in lean and obese mice. Effects of UnAG 
overexpression in transgenic Myh6/Ghrl (Tg) vs. wild type (Wt) mice fed 16 wks with Control- 
(CD) or High Fat- Diet (HFD) on total (A) and oxidized (GSSG) over total (B, GSH: reduced) 
glutathione, on tissue expression of IL-1α (C), IL-1β (D), TNFα (E), IL-6 (F) and IL-10 (G) 
measured by xMAP technology in gastrocnemius muscle. Effects of UnAG overexpression on the 
phosphorylation of insulin receptor (IRY1162/Y1163, H), IRS-1S312 (I), AKTS473 (J), GSK-3βS9 (K), 
PRAS40T246 (L), P70S6KT421/S424 (M) measured by xMAP technology in gastrocnemius muscle. 
Absolute (N), corresponding Area Under the Curve (AUC; O), and relative (P) blood glucose 
values in Insulin Tolerance Test (ITT) experiments. *p<0.05 vs. Ct; †p<0.05 vs. same genotype-
CD; ‡p<0.05 vs. other genotype-CD; mean±SEM, n=7/group. 
Figure 5. In vitro impact of UnAG on cultured myotubes. Effects of 48 h incubation with 
increasing concentrations of acylated (AG) or unacylated ghrelin (UnAG) vs. control (Ct) on 
isolated mitochondria H2O2 synthesis rate with different respiratory substrates (A, GMS: 
Glutamate+Succinate+Malate; S: Succinate; GM: Glutamate+Malate; PCM: Palmitoyl-L-
Carnintine+Malate) and effects of the above treatments on the phosphorylation of insulin receptor 
(IR)Y1162/Y1163 (B), IRS-1S312 (C), AKTS473 (D), GSK-3βS9 (E), PRAS40T246 (F), P70S6KT421/S424 (G) 
measured by xMAP technology in C2C12 myotubes. U CS: units of citrate synthase. *p<0.05 vs. 
Ct; †p<0.05 vs. same hormone 0.1µM; ‡p<0.05 vs. same hormone 0.5µM; § p<0.05 vs. AG, same 
concentration; $p<0.05 vs. other hormone 0.5µM; ¶p<0.05 vs. other hormone 0.1µM; #p<0.05 vs. 
all other groups; mean±SEM, n=3/group. 
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Figure 6. Impact of UnAG on mitochondrial ATP synthesis. Effects on muscle ATP synthesis 
rate with different respiratory substrates (A, PPKM: Pyruvate+Palmitoyl-L-Carnintine+α-
Ketoglutarate+Malate; PCM: Palmitoyl-L-Carnintine+Malate;  GM: Glutamate+Malate;  SR: 
Succinate+Rotenone) in isolated mitochondria from rat gastrocnemious muscle after unacylated 
ghrelin (UnAG, 200µg subcutaneous injection twice per day) vs. saline (Ct) sustained 4-day (A, 
n=8-10/group) treatment, in isolated mitochondria from gastrocnemious muscle of mice with UnAG 
up-regulation (Tg Myh6/Ghrl) vs. wild type (wt) fed 16 wks with Control- (CD) or High Fat- Diet 
(HFD) (B, n=7/group) and in C2C12 myotubes after 48 h incubation with increasing concentrations 
of acylated (AG) or unacylated ghrelin (UnAG) vs. control (Ct) in (C, n=3/treatment).  Complex I 
over complex II related ATP synthesis rate ratio in rat gastrocnemius muscle after sustained 
treatment (D) and in cultured myotubes (E). *p<0.05 vs. Ct or Wt; †p<0.05 vs. same genotype-CD; 
‡p<0.05 vs. other genotype-CD; § p<0.05 vs. AG, same concentration; #p<0.05 vs. all other groups; 
mean±SEM. 
Figure 7. Role of autophagy in UnAG effects on mitochondrial ROS generation and insulin 
signalling. Effects of autophagy mediator ATG5 genomic silencing vs. non targeting NT4 siRNA 
transfection on C2C12 myotubes after 48 h incubation with increasing concentrations of acylated 
(AG) or unacylated ghrelin (UnAG) vs. control (Ct) on isolated mitochondria H2O2 synthesis rate 
with different respiratory substrates (A, GMS: Glutamate+Succinate+Malate; S: Succinate; GM: 
Glutamate+Malate; PCM: Palmitoyl-L-Carnintine+Malate) and cell protein expression of ATG5 
after transfection with the two siRNA (B). Effects of the above treatments on the phosphorylation 
of insulin receptor (IR)Y1162/Y1163 (C), IRS-1S312 (D), AKTS473 (E), GSK-3βS9 (F), PRAS40T246 (G), 
P70S6KT421/S424 (H) measured by xMAP technology. Autophagy activation marker LC3II/LC3I as 
measured by western blot in the gastrocnemious muscle of mice with UnAG up-regulation (Tg 
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Myh6/Ghrl) vs. wild type (wt) fed 16 wks with Control- (CD) or High Fat- Diet (HFD) (I, 
n=7/group) with representative blot. U CS: units of citrate synthase. *p<0.05 vs. NT4, same UnAG 
concentration; †p<0.05 vs. same siRNA, no UnAG; ‡p<0.05 vs. other siRNA, no UnAG; § p<0.05 
vs. same siRNA, UnAG 0.1µM; § p<0.05 vs. other siRNA, UnAG 0.1µM; #p<0.05 vs. all other 
groups; mean±SEM; n=3/group. 
Figure 8: Proposed interactions between UnAG and clustered obesity-associated metabolic 
alterations in skeletal muscle of high-fat diet-induced obese rodents: higher mitochondrial 
production of reactive oxygen species (ROS), higher inflammation and lower insulin signalling 
activation are normalized by chronic UnAG over-exposure. Our findings further demonstrate a 
direct effect of UnAG to lower mitochondrial ROS production through stimulated autophagy, 
which may directly lead to lower inflammation and enhanced insulin signalling. Potential parallel 
UnAG activities to directly lower inflammation and enhance insulin signalling should be further 
investigated. 
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Supplementary Figure Legends 
Supplementary Figure 1. UnAG and IRS-1Y612 phosphorylation in skeletal muscle. Effects 
of unacylated ghrelin (UnAG, 200µg subcutaneous injection twice per day) vs. saline (Ct) 
sustained 4-day treatment (A, n=8-10/group), or of UnAG up-regulation in transgenic 
Myh6/Ghrl (Tg) vs. wild type (Wt) mice fed 16 wks with Control- (CD) or High Fat- Diet (HFD) 
(B, n=7/group) on the phosphorylation of IRS-1Y612 in gastrocnemius muscle with representative 
blots. OD: optical density. Mean±SEM.  
 
Supplementary Figure 2. UnAG and liver redox state and inflammation. Effects of 
unacylated ghrelin (UnAG, 200µg subcutaneous injection twice per day) vs. saline (Ct) sustained 
4-day treatment on overall (A) and specific superoxide production from mitochondrial sources in 
whole tissue homogenate (B), on intact isolated mitochondria H2O2 synthesis rate with different 
respiratory substrates (C, GMS: Glutamate+Succinate+Malate; S: Succinate; GM: 
Glutamate+Malate; PCM: Palmitoyl-L-Carnintine+Malate) and on superoxide generation from 
nitric oxide synthase (D), NADPH oxidase (E) and xanthine oxidase (F) in rat liver. Effects of 
UG treatment on total (G) and oxidized (GSSG) over total (H, GSH: reduced) tissue glutathione, 
and on the binding activity of NF-κB (I), with representative blot, in rat liver. U CS: units of 
citrate synthase; a.u.: arbitrary units, Ab: antibody. Mean±SEM, n=8-10/group.  
Supplementary Figure 3. UnAG and liver insulin action and ATP synthesis. Effects of 
unacylated ghrelin (UnAG, 200µg subcutaneous injection twice per day) vs. saline (Ct) sustained 
4-day treatment on the phosphorylation of insulin receptor (IR)Y1162/Y1163 (A), IRS-1S312 (B), 
AKTS473 (C), GSK-3βS9 (D), PRAS40T246 (E), P70S6KT421/S424 (F) measured by xMAP 
technology, and on isolated mitochondrial ATP synthesis rate with different respiratory 
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substrates (E, PPKM: Pyruvate+Palmitoyl-L-Carnintine+α-Ketoglutarate+Malate; PCM: 
Palmitoyl-L-Carnintine+Malate;  GM: Glutamate+Malate;  SR: Succinate+Rotenone) in rat liver. 
Mean±SEM, n=8-10/group. 
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Supplementary figure 3
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